Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Gynecologic Oncology

Surgical Treatment and Localized Care

At a Glance

Early-stage endometrial cancer is usually treated with surgery to remove the uterus, cervix, fallopian tubes, and ovaries, while also providing staging information. Sentinel node mapping, radiation, chemotherapy, or fertility-sparing progestins may be considered based on cancer risk and their goals.

For most people diagnosed with early-stage endometrial cancer, surgery is the primary treatment. The goal is two-fold: to remove the cancer and to “stage” it—providing the essential information about whether the cancer has spread beyond the uterus. This information, combined with the tumor’s molecular profile, determines your overall risk group and whether adjuvant (follow-up) treatment is needed.

The Surgical Foundation

The standard operation for early-stage disease is a total hysterectomy (removal of the uterus and cervix) and a bilateral salpingo-oophorectomy (removal of both fallopian tubes and ovaries) [1].

In most cases, this is done using minimally invasive surgery (laparoscopic or robotic-assisted). This approach uses small incisions, which typically leads to less pain, a shorter hospital stay, and a faster recovery compared to traditional “open” surgery [2]. For some young patients with very low-risk cancer, it may be carefully considered to keep the ovaries to avoid immediate menopause, though this requires a detailed discussion with your surgeon about the potential risks [3].

Modern Lymph Node Assessment

A critical part of the surgery is checking the lymph nodes. In the past, surgeons performed a “full lymphadenectomy,” removing dozens of nodes. Today, for appropriate patients, the preferred method is Sentinel Lymph Node (SLN) mapping [1].

  • How it works: A dye (often indocyanine green) is injected into the cervix. The “sentinel” nodes—the very first nodes where cancer cells would travel—soak up the dye and are removed for testing [4].
  • The Benefits: SLN mapping is highly accurate while significantly reducing (though not entirely eliminating) the risk of lymphedema (chronic, treatable swelling in the legs) [4][5]. While about 49% of patients who have all nodes removed may experience some swelling, that number drops to about 26% with the sentinel node approach [5].
  • If Mapping Fails: Sometimes the dye does not travel to a node on one or both sides. In this case, the surgeon may need to remove more lymph nodes from that side to ensure accurate staging.

Risk-Adapted Radiation Therapy

Adjuvant treatment is based on an integrated risk assessment involving your stage, histology, grade, molecular subtype, LVSI, age, and overall health. Not everyone needs radiation [6][7].

If radiation is recommended, there are two main types:

  1. Vaginal Brachytherapy (VBT): This is a localized treatment where a radioactive source is placed inside the vagina for a few minutes over a series of visits. It is highly effective at preventing the cancer from returning to the “vaginal cuff” (the top of the vagina) [8]. While it targets a smaller area, it is not side-effect free; it can cause vaginal dryness, shortening, narrowing (stenosis), and discomfort during intercourse [9].
  2. External Beam Radiation Therapy (EBRT): This involves daily treatments over several weeks from a machine outside the body. It covers a larger area, including the pelvic lymph nodes [6]. EBRT is considered for patients with higher-risk features (such as stage III disease, aggressive histology, p53-abnormal biology, or substantial LVSI combined with other factors) [7][10]. EBRT carries a higher risk of long-term bowel and bladder changes.

The Role of Chemotherapy

While radiation focuses on the pelvic area, chemotherapy travels through the entire body. For early-stage disease, chemotherapy is not standard for everyone. It is typically considered for:

  • High-risk histologies: Such as serous, clear cell, or carcinosarcoma [11][12].
  • Aggressive Molecular Subtypes: Patients with the p53-abnormal subtype may benefit from a combination of chemotherapy and radiation [13][14].

Fertility-Sparing Options

For young patients who wish to preserve fertility, conservative management with progestin therapy is sometimes an option, but it has strict boundaries [15][16].

This path requires a high level of commitment:

  • Strict Criteria: It is generally reserved for patients with expert-confirmed, low-grade (Grade 1) endometrioid cancer completely confined to the endometrium, with no myometrial invasion or extrauterine disease [15]. Assessment for Lynch syndrome is also required.
  • Frequent Monitoring: High-dose progestins are used to try to induce a complete response. You will need strict biopsies every 3 to 6 months to ensure the cancer is responding [16][17].
  • The Goal: If the cancer responds completely, pregnancy can be considered, often with a fertility specialist [18][19]. Because of the high risk of recurrence, a definitive hysterectomy is usually discussed and recommended after childbearing is complete or if the treatment fails [20].

Common questions in this guide

What surgery is usually used for early-stage endometrial cancer?
For most people with early-stage endometrial cancer, the standard operation is a total hysterectomy, which removes the uterus and cervix, along with removal of both fallopian tubes and ovaries. Surgeons often use minimally invasive laparoscopic or robotic methods, which usually mean less pain, a shorter hospital stay, and faster recovery than open surgery.
How does sentinel lymph node mapping help during endometrial cancer surgery?
A dye placed in the cervix helps the surgeon find the first lymph nodes where cancer cells are likely to travel, and those nodes are removed for testing. This can provide accurate staging with less lymphedema risk than removing many lymph nodes, although swelling can still occur; if mapping fails on one side, more nodes may need removal there.
How is radiation chosen after endometrial cancer surgery?
The decision considers the cancer’s stage, cell type, grade, molecular subtype, whether cancer cells are in small lymphatic or blood vessels, age, and overall health. Vaginal brachytherapy treats the top of the vagina and may reduce recurrence there, while external beam radiation covers more of the pelvis and is more often considered when risk is higher.
Is chemotherapy needed for every person with early-stage endometrial cancer?
No. It is usually reserved for cancers with high-risk cell types, such as serous, clear cell, or carcinosarcoma, and may be considered for a high-risk molecular pattern called p53-abnormal; some higher-risk cases receive chemotherapy with radiation.
Can I preserve fertility after an endometrial cancer diagnosis?
Sometimes, but only under strict conditions: the cancer must be expert-confirmed, low-grade grade 1 endometrioid cancer confined to the uterine lining, without invasion into uterine muscle or spread outside the uterus, and Lynch syndrome must be assessed. High-dose progestin therapy requires biopsies every 3 to 6 months; if it does not work or after childbearing, a definitive hysterectomy is usually discussed.

Get notified when new evidence is published on endometrial cancer.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (20)
  1. 1

    Sentinel lymph node mapping in endometrial cancer: Current evidence and practice.

    Salman L, Cusimano MC, Marchocki Z, Ferguson SE

    Journal of surgical oncology 2024; (129(1)):117-119 doi:10.1002/jso.27550.

    PMID: 38059317
  2. 2

    Sentinel lymph node biopsy for robotic-assisted endometrial cancer staging: further improvement of perioperative outcomes.

    Casarin J, Multinu F, Tortorella L, et al.

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2020; (30(1)):41-47 doi:10.1136/ijgc-2019-000672.

    PMID: 31780567
  3. 3

    Clinical issues of surgery for uterine endometrial cancer in Japan.

    Nagai T, Shimada M, Tokunaga H, et al.

    Japanese journal of clinical oncology 2022; (52(4)):346-352 doi:10.1093/jjco/hyab211.

    PMID: 35032166
  4. 4

    A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study.

    Rossi EC, Kowalski LD, Scalici J, et al.

    The Lancet. Oncology 2017; (18(3)):384-392 doi:10.1016/S1470-2045(17)30068-2.

    PMID: 28159465
  5. 5

    Reduced lymphedema after sentinel lymph node biopsy versus lymphadenectomy for endometrial cancer.

    Glaser G, Dinoi G, Multinu F, et al.

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2021; (31(1)):85-91 doi:10.1136/ijgc-2020-001924.

    PMID: 33243776
  6. 6

    Postoperative Radiation Therapy for Endometrial Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline.

    Meyer LA, Bohlke K, Powell MA, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015; (33(26)):2908-13 doi:10.1200/JCO.2015.62.5459.

    PMID: 26150442
  7. 7

    Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials.

    Bosse T, Peters EE, Creutzberg CL, et al.

    European journal of cancer (Oxford, England : 1990) 2015; (51(13)):1742-50.

    PMID: 26049688
  8. 8

    Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy.

    Wortman BG, Creutzberg CL, Putter H, et al.

    British journal of cancer 2018; (119(9)):1067-1074 doi:10.1038/s41416-018-0310-8.

    PMID: 30356126
  9. 9

    Prognostic factors for long-term quality of life after adjuvant radiotherapy in women with endometrial cancer.

    Foerster R, Schnetzke L, Bruckner T, et al.

    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 2016; (192(12)):895-904 doi:10.1007/s00066-016-1037-1.

    PMID: 27605238
  10. 10

    External beam radiotherapy versus vaginal brachytherapy in patients with stage II endometrial cancer: a systematic review and meta-analysis.

    Narasimhulu DM, Cope A, Riaz IB, et al.

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2020; (30(6)):797-805 doi:10.1136/ijgc-2020-001199.

    PMID: 32221021
  11. 11

    Radiation Therapy for Endometrial Cancer: An American Society for Radiation Oncology Clinical Practice Guideline.

    Harkenrider MM, Abu-Rustum N, Albuquerque K, et al.

    Practical radiation oncology 2023; (13(1)):41-65 doi:10.1016/j.prro.2022.09.002.

    PMID: 36280107
  12. 12

    Adjuvant chemotherapy in endometrial cancer.

    Gómez-Raposo C, Merino Salvador M, Aguayo Zamora C, Casado Saenz E

    Cancer chemotherapy and pharmacology 2020; (85(3)):477-486 doi:10.1007/s00280-019-04027-6.

    PMID: 31950214
  13. 13

    Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts.

    Stelloo E, Nout RA, Osse EM, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2016; (22(16)):4215-24 doi:10.1158/1078-0432.CCR-15-2878.

    PMID: 27006490
  14. 14

    PErsonalized TReatment for Endometrial Carcinoma (PETREC): study design and methods of a prospective Finnish multicenter trial.

    Loukovaara M, Bützow R, Staff S, et al.

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2023; (33(11)):1807-1811 doi:10.1136/ijgc-2023-004939.

    PMID: 37813479
  15. 15

    Fertility-preservation in endometrial cancer: is it safe? Review of the literature.

    Carneiro MM, Lamaita RM, Ferreira MC, Silva-Filho AL

    JBRA assisted reproduction 2016; (20(4)):232-239 doi:10.5935/1518-0557.20160045.

    PMID: 28050959
  16. 16

    Fertility-sparing treatment in women with endometrial cancer.

    Won S, Kim MK, Seong SJ

    Clinical and experimental reproductive medicine 2020; (47(4)):237-244 doi:10.5653/cerm.2020.03629.

    PMID: 33181010
  17. 17

    Fertility-sparing treatments for patients with endometrial cancer: A comprehensive review.

    Seol A, Jeong HG, Kim S, Lee S

    Clinical and experimental reproductive medicine 2026; (53(1)):1-9 doi:10.5653/cerm.2023.06814.

    PMID: 41069261
  18. 18

    Conservative treatment of endometrial cancer in women of reproductive age (Review).

    Bourou MZ, Matsas A, Vrekoussis T, et al.

    Molecular and clinical oncology 2023; (19(1)):55 doi:10.3892/mco.2023.2651.

    PMID: 37323245
  19. 19

    Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women.

    Uccella S, Zorzato PC, Dababou S, et al.

    Medicina (Kaunas, Lithuania) 2022; (58(9)) doi:10.3390/medicina58091256.

    PMID: 36143933
  20. 20

    Comparison of oncologic outcomes between completion hysterectomy and no completion hysterectomy in patients who achieved complete response and completed childbearing after fertility-sparing treatment for early-stage endometrial cancer: Gynecologic Oncology Research Investigators coLLaborAtion study (GORILLA-3001).

    Lee AJ, Jang EB, Suh DH, et al.

    Gynecologic oncology 2025; (203()):191-197 doi:10.1016/j.ygyno.2025.10.036.

    PMID: 41237702

This page describes surgical, radiation, chemotherapy, and fertility-sparing options for endometrial cancer for informational purposes only; it does not constitute medical advice. Your gynecologic oncology team can tailor recommendations to your cancer, health, and fertility goals.

Guide contents endometrial cancer
Research & Literature
03 Deciphering Your Pathology and Stage 05 Treating Advanced and Recurrent Disease